62 filings
8-K
SABS
SAB Biotherapeutics Inc
30 May 24
SAB Biotherapeutics Announces Departure of Chief Financial Officer
6:49pm
8-K
SABS
SAB Biotherapeutics Inc
21 May 24
This regulatory clearance enables clinical development of SAB-142 in patients with type 1 diabetes in the US
7:30am
8-K
SABS
SAB Biotherapeutics Inc
15 Apr 24
Regulation FD Disclosure
5:15pm
8-K
SABS
SAB Biotherapeutics Inc
29 Mar 24
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
9:35am
8-K
SABS
SAB Biotherapeutics Inc
8 Mar 24
Entry into a Material Definitive Agreement
4:30pm
8-K
y7c0q8tpcvjy2fap
2 Feb 24
SAB Biotherapeutics Announces Executive Leadership Change
7:53am
8-K
08c esk783
26 Jan 24
Entry into a Material Definitive Agreement
4:15pm
8-K
p4dj6joxkeq80g8u3u
25 Jan 24
Other Events
5:00pm
8-K
geukflbixw9v55
19 Jan 24
Regulation FD Disclosure
4:21pm
8-K
76dg61i
3 Jan 24
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
9:00am
8-K
ad9urly cxjwp1s88
29 Nov 23
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying
7:40am
8-K
7p8q90p9mwoy 4f2i9zf
22 Nov 23
Amendments to Articles of Incorporation or Bylaws
4:45pm
8-K
2t8rrwpf
20 Nov 23
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
5:00pm
8-K/A
6guorov87 u1
14 Nov 23
Unregistered Sales of Equity Securities
4:31pm
8-K
e85z 5uol6tmgqah4
27 Oct 23
Entry into a Material Definitive Agreement
5:00pm
8-K
qs8l58 k4
2 Oct 23
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
4:10pm
8-K
281r5 rks
21 Aug 23
Changes in Registrant's Certifying Accountant
8:25am
8-K
5673r rq1ei2
31 Jul 23
Changes in Registrant's Certifying Accountant
4:43pm
8-K
6v2yln sg
3 Jul 23
Submission of Matters to a Vote of Security Holders
1:20pm
8-K
9p30jc5bl8h
21 Jun 23
Regulation FD Disclosure
8:50am